Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chelsee Jensen

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal of Managed Care & Specialty Pharmacy|August 31, 2021
The high cost burden of third- to fifth-line treatments for multiple myeloma: unsustainable and unaffordableChelsee Jensen
JAMA|June 29, 2026
Pricing for Oncology BiosimilarsChelsee Jensen, Eric Tichy
JCO Oncology Practice|July 14, 2025
Subcutaneous Immunotherapies in Solid Tumors: Are We Truly Expanding Access and Efficiency?Gogo-Ogute Ibodeng, Chelsee Jensen, Scott A Soefje, et al.
Current Hematologic Malignancy Reports|July 21, 2023
Multiple Myeloma: Current Clinical Landscape and Compounding CostsKelsey Beck, Tyler Sandahl, Sikander Ailawadhi, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 24, 2020
Non-neutralizing antibodies and limitations of serologic testing for severe acute respiratory syndrome coronavirus 2 in patients receiving immunoglobulin replacement productsDeepti Vellaichamy Manian, Chelsee Jensen, Elitza S Theel, et al.
Mayo Clinic Proceedings|December 3, 2023
Analysis of Medicare Expenditure for Discarded Infused Cancer Therapeutics From 2017-2020Aakash Desai, Alexander Xiao, Caleb Smith, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal of Managed Care & Specialty Pharmacy|August 31, 2021
The high cost burden of third- to fifth-line treatments for multiple myeloma: unsustainable and unaffordableChelsee Jensen
JAMA|June 29, 2026
Pricing for Oncology BiosimilarsChelsee Jensen, Eric Tichy
JCO Oncology Practice|July 14, 2025
Subcutaneous Immunotherapies in Solid Tumors: Are We Truly Expanding Access and Efficiency?Gogo-Ogute Ibodeng, Chelsee Jensen, Scott A Soefje, et al.
Current Hematologic Malignancy Reports|July 21, 2023
Multiple Myeloma: Current Clinical Landscape and Compounding CostsKelsey Beck, Tyler Sandahl, Sikander Ailawadhi, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 24, 2020
Non-neutralizing antibodies and limitations of serologic testing for severe acute respiratory syndrome coronavirus 2 in patients receiving immunoglobulin replacement productsDeepti Vellaichamy Manian, Chelsee Jensen, Elitza S Theel, et al.
Mayo Clinic Proceedings|December 3, 2023
Analysis of Medicare Expenditure for Discarded Infused Cancer Therapeutics From 2017-2020Aakash Desai, Alexander Xiao, Caleb Smith, et al.
Pageof 1